GTC Biotherapeutics (fka GTCB)

[go seek]

From RMF Results from the phase-2 ATryn study in DIC. The latest guidance from GTC’s partner, Leo Pharma, is for completion of enrollment by the end of 2008 and reporting of data in 1H09. This study will be closely watched by the investment community because DIC—and other acquired antithrombin deficiencies—address a much larger market than hereditary deficiency.

...it is my understanding this study is a dosing range study, and is not set up for efficacy results. What could we learn from the P2 study that will be of interest to the investment community?

thanks